<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124461">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02011373</url>
  </required_header>
  <id_info>
    <org_study_id>2013.804</org_study_id>
    <nct_id>NCT02011373</nct_id>
  </id_info>
  <brief_title>Efficacy of IFABONDTM Synthetic Glue for Fixation of Implanted Material in Laparoscopic Sacrocolpopexy: a Prospective Multicenter Study</brief_title>
  <acronym>PRO-COLLE</acronym>
  <official_title>Efficacy of IFABONDTM Synthetic Glue for Fixation of Implanted Material in Laparoscopic Sacrocolpopexy: a Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vitalitec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laparoscopic sacrocolpopexy is the consensual attitude of choice in genital prolapse but
      incurs problems of tolerance of implanted material. As an alternative to stapling and
      suturing, which cause vaginal erosion, we present a fixation technique using a sterile
      synthetic liquid tissue glue: IFABOND™. A non-randomised prospective multicenter study will
      assess efficacy in terms of 12-month failure of prolapse correction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage prolapse correction failure</measure>
    <time_frame>12 months post-surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage prolapse correction failure</measure>
    <time_frame>24 months post-surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage immediate postoperative failure</measure>
    <time_frame>1 month post-surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications rate</measure>
    <time_frame>Peroperative and 1, 12 and 24 months post-surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>1, 12 and 24 months post-surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Medial and/or Anterior Genital Prolapse</condition>
  <arm_group>
    <arm_group_label>IFABOND</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fixation technique using a sterile synthetic liquid tissue glue: IFABOND™</intervention_name>
    <arm_group_label>IFABOND</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman aged 18 years or more

          -  Stage III or IV medial and/or anterior genital prolapse on the Pelvic Organ Prolapse
             Quantification (POP-Q) classification (hysterocele and/or cystocele), requiring
             surgical correction

          -  Patient requesting surgery for the trouble caused by the prolapse

        Exclusion Criteria:

          -  Prolapse of POP-Q stage &lt;III or without functional impact

          -  Unacceptable postoperative risk disclosed on interview: coagulation disorder, immune
             disorder, evolutive disease, etc.

          -  Impaired lower-limb range of motion preventing positioning for surgery

          -  Pregnancy or intended pregnancy during study period

          -  Evolutive or latent infection or signs of tissue necrosis on clinical examination

          -  Non-controlled diabetes (glycated haemoglobin &gt;8%)

          -  Treatment impacting immune response (immunomodulators), ongoing or within previous
             month

          -  History of pelvic region radiation therapy, at any time

          -  History of pelvic cancer

          -  Non-controlled evolutive spinal pathology

          -  Known hypersensitivity to one of the implant components (polypropylene)

          -  Cyanoacrylate hypersensitivity

          -  Formaldehyde hypersensitivity

          -  Inability to understand information provided

          -  No  national health insurance cover; prisoner, or ward of court
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gery Lamblin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynaecology Department, Hôpital Femme Mère Enfant, Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphanie Ms Moret</last_name>
    <phone>4 72 35 58 78</phone>
    <phone_ext>+33</phone_ext>
    <email>stephanie.moret@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gynaecology Department, Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Moret</last_name>
      <phone>4 72 35 58 78</phone>
      <phone_ext>+33</phone_ext>
      <email>stephanie.moret@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gery Lamblin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Chabert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynaecology Department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gil Dubernard, MD</last_name>
      <phone>472072866</phone>
      <phone_ext>+33</phone_ext>
      <email>gil.dubernard@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Jousselin de Saint Hilaire, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gil Dubernard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynaecology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Golfier, MD</last_name>
      <phone>478864179</phone>
      <phone_ext>+33</phone_ext>
      <email>francois.golfier@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Daniel Raudrant, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Golfier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>December 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prolapse, laparoscopic sacrocolpopexy, IFABONDTM glue</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Genital Diseases, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
